Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(2;11)(p21;q23)

Identity

 
  t(2;11)(p21;q23) G- banding (left) - Courtesy Eric Crawford, and R- banding (Editor)

Clinics and Pathology

Disease myelodysplastic syndromes (MDS), acute non lymphocytic leukemia (ANLL) and acute lymphoblastic leukemia (ALL)
Phenotype / cell stem origin 20 cases were documented, 14 of them were MDS; in three cases, type of MDS was not described; the remaining cases were: 2 AISA, 5 RA and 4 RAEB; in 6 patients, MDS has transformed into ANLL (M1, M5a, M6 and unidentified); in 6 cases acute leukemia was diagnosed : 4 ANLL, 2 ALL; ANLL FAB-types were: M0 evolving into M4, M1, M2 and atypical M3
Epidemiology male predominance: 13 M:7 F; the majority of patients (16 out of 20) were over 50 years of age and 8 of them were over 60 years of age
Clinics variable
Prognosis due to heterogeneity of cases and lack of molecular data, the prognostic importance of t(2;11)(p21;q23) cannot be assessed; in 6 cases of MDS transformation into ANLL, MDS phase varied from 18 mths to 5 yrs; in 4 out of 5 ANLL cases treated in 1986-1993, remission duration varied from 6 to 13 mths

Cytogenetics

Cytogenetics Morphological a high variability of breakpoints on both chromosome 2 (2p16-2p21) and chromosome 11 (11q13-11q25) were found by conventional cytogenetics
Cytogenetics Molecular MLL gene involvement was observed in 2 out of 3 cases studied
Additional anomalies additional abnormalities were observed in 10 out of 20 cases; in 8 cases, del(5)(q13q33) is found; it is of note, that deletions of 5q usually are not seen in cases with MLL-associated translocations

Genes involved and Proteins

Note the gene involved in 2p in unknown
Gene Name MLL
Location 11q23
Dna / Rna 37 exons, spanning about 120 kb; 13-15 mRNA
Protein 431 kD; transcriptional regulatory factor, nuclear localization; Contains two DNA binding motifs (a AT hook and zinc fingers), a DNA methyl transferase motif

Result of the chromosomal anomaly

Hybrid gene
Description unknown
  
Fusion Protein
Description unknown
  

External links

Other databaset(2;11)(p21;q23) Mitelman database (CGAP - NCBI)

Bibliography

A 2p;11q chromosome translocation in dysmyelopoietic preleukemia.
Feder M, Finan J, Besa E, Nowell P
Cancer genetics and cytogenetics. 1985 ; 15 (1-2) : 143-150.
PMID 3967213
 
Translocation (2;11) (p21;q23) in acute non-lymphocytic leukaemia: a non-random association.
de la Chapelle A, Knuutila S, Elonen E
Scandinavian journal of haematology. Supplementum. 1986 ; 45 : 91-97.
PMID 3457447
 
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.
Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R, Sandberg AA
The New England journal of medicine. 1993 ; 329 (13) : 909-914.
PMID 8361504
 
MLL is involved in a t(2;11)(p21;q23) in a patient with acute myeloblastic leukemia.
Fleischman EW, Reshmi S, Frenkel MA, Konovalova WI, Guleva GP, Kulagina OE, Konstantinova LN, Tupitsyn NN, Rowley JD
Genes, chromosomes & cancer. 1999 ; 24 (2) : 151-155.
PMID 9885982
 

Contributor(s)

Written01-2000Elena W Fleischman
Cancer Research Center, Moscow, Russia

Citation

This paper should be referenced as such :
Fleischman EW . t(2;11)(p21;q23). Atlas Genet Cytogenet Oncol Haematol. January 2000 .
URL : http://AtlasGeneticsOncology.org/Anomalies/t0211ID1109.html

This paper is referenced by INIST as such :
http://documents.irevues.inist.fr/bitstream/2042/37584/1/01-2000-t0211ID1109.pdf   [ Bibliographic record ]

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Mar 9 12:36:52 CET 2013

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.